

# Gordon Mallarkey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2414849/publications.pdf>

Version: 2024-02-01

28  
papers

327  
citations

1170033

9  
h-index

1051228

16  
g-index

28  
all docs

28  
docs citations

28  
times ranked

440  
citing authors

#	ARTICLE	IF	CITATIONS
1	What we are doing to help researchers publish their papers in our journal. Journal of International Medical Research, 2022, 50, 030006052211009.	0.4	0
2	Therapeutic management of hyperlipoproteinemia (a). Drugs in Context, 2019, 8, 1-11.	1.0	14
3	Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs in Context, 2018, 7, 1-10.	1.0	41
4	European Society for Medical Oncology Copenhagen update: potential practice-changing findings. Therapeutic Advances in Medical Oncology, 2017, 9, 4-12.	1.4	0
5	Latest therapeutic advances in musculoskeletal disease from the ACR 2015 annual conference. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 8-14.	1.2	0
6	Osteoporosis therapeutics: recent developments at ASBMR. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 3-7.	1.2	2
7	Targeting precision medicine toxicity: recent developments. Therapeutic Advances in Drug Safety, 2015, 6, 4-14.	1.0	4
8	Targeted therapies in medical oncology: successes, failures and next steps. Therapeutic Advances in Medical Oncology, 2013, 5, 5-16.	1.4	10
9	Latest advances in the medical treatment of cancer: a 2011 snapshot. Therapeutic Advances in Medical Oncology, 2012, 4, 3-8.	1.4	0
10	Latest drug safety alerts from the 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Therapeutic Advances in Drug Safety, 2012, 3, 5-11.	1.0	0
11	Pathways and biomarkers in breast cancer: latest evidence. Therapeutic Advances in Medical Oncology, 2012, 4, 157-166.	1.4	0
12	Looking at the causes of, and possible treatments for, psychiatric diseases: gene-environment interactions, circadian rhythms and neuronal dysfunction. Therapeutic Advances in Chronic Disease, 2011, 2, 5-8.	1.1	0
13	Latest advances in medical oncology: highlights from Milan ESMO 2010 annual congress. Therapeutic Advances in Medical Oncology, 2011, 3, 3-9.	1.4	2
14	Advancing breast cancer therapy by translational research: highlights of the Improving Care and Knowledge through Translational Research (IMPAKT) breast cancer conference. Therapeutic Advances in Medical Oncology, 2011, 3, 223-227.	1.4	2
15	Drug safety advances from ICPE 2010. Therapeutic Advances in Drug Safety, 2010, 1, 45-52.	1.0	0
16	Highlights of the 2nd European Lung Cancer Conference. Therapeutic Advances in Medical Oncology, 2010, 2, 297-299.	1.4	0
17	Latest therapeutic advances from the ASCO 2010 Annual Meeting. Therapeutic Advances in Medical Oncology, 2010, 2, 347-350.	1.4	0
18	Pharmacovigilance and pharmacogenetic discussions at WorldPharma 2010. Therapeutic Advances in Drug Safety, 2010, 1, 7-10.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Liaison between public hospital staff and the pharmaceutical industry: guidance from the NSW Therapeutic Advisory Group. <i>Medical Journal of Australia</i> , 2009, 190, 406-407.	0.8	1
20	An Evaluation of Eptacog Alfa in Nonhaemophiliac Conditions. <i>Drugs</i> , 2008, 68, 1665-1689.	4.9	15
21	Editorial: What are the therapeutic advances in gastroenterology? Opinions from world experts. <i>Therapeutic Advances in Gastroenterology</i> , 2008, 1, 85-90.	1.4	0
22	What are the therapeutic advances in neurology? Opinions from world experts. <i>Therapeutic Advances in Neurological Disorders</i> , 2008, 1, 5-12.	1.5	11
23	Review: Efficacy and safety of adalimumab in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2008, 1, 43-50.	1.4	26
24	Accuracy of packaging of dose administration aids in regional aged care facilities in the Hunter area of New South Wales. <i>Medical Journal of Australia</i> , 2008, 188, 280-282.	0.8	26
25	Esomeprazole. <i>Drugs</i> , 2002, 62, 1503-1538.	4.9	135
26	A comparative study of the involvement of the prostaglandin H <sub>2</sub> /thromboxane A <sub>2</sub> pathway in intravascular platelet aggregation in guinea pigs and rats. <i>British Journal of Pharmacology</i> , 1985, 84, 425-430.	2.7	19
27	<i>In vivo</i> platelet aggregation in the rat: dependence on extracellular divalent cation and inhibition by nonsteroidal anti-inflammatory drugs. <i>British Journal of Pharmacology</i> , 1984, 81, 31-39.	2.7	12
28	The effect of arachidonic acid metabolism on intravascular platelet aggregation in rats. <i>Thrombosis Research</i> , 1984, 36, 91-102.	0.8	7